Core Insights - A delegation of Chinese private enterprises, organized by TOJOY Enterprise Service, engaged in business discussions with Saudi Arabia's Ministry of Investment, focusing on investment opportunities across various sectors [1][2] - The discussions highlighted Saudi Arabia's commitment to diversifying its economy under Vision 2030, particularly in sectors like new energy, healthcare, and infrastructure, which align with the strengths of Chinese enterprises [3] Group 1: Investment Opportunities - The meeting covered potential cooperation in infrastructure, healthcare, artificial intelligence, and smart transportation, with both sides expressing preliminary cooperation intentions [5] - TOJOY Enterprise Service aims to facilitate better understanding of local policies and business environments for Chinese enterprises, promoting collaboration from product levels to broader industrial-chain integration [3][5] Group 2: Strategic Focus - Mr. Ge Jun emphasized the importance of a long-term perspective for Chinese enterprises entering Middle Eastern markets, advocating for localization and compliance with local regulations [4] - Several companies in the delegation have already initiated the process of registering their businesses in Saudi Arabia, indicating a proactive approach to market entry [4]

Core Insights - Faraday Future has launched the FX Super One in the UAE, marking a significant step in its global strategy and the beginning of deliveries in the region [4][6] - The company aims to establish the FX Super One as a leading model in the Middle East MPV segment, with soccer legend Andrés Iniesta as the first global owner and Co-Creation Officer [3][5] - The FX Super One is available in two powertrain options, with the first model priced at AED 309,000 (approximately USD 84,000), and has already received over 200 non-binding preorders within 48 hours of its launch [4][5] Company Strategy - The delivery to Iniesta signifies the start of FX Super One deliveries in the UAE and supports the company's sales efforts in the region [4] - The launch aligns with Faraday Future's Global Automotive Bridge Strategy, transitioning from operational to revenue phases in the UAE [6] - The FX strategy focuses on introducing mass production models with luxury technology, targeting a broader market with middle-to-low price range offerings [6] Market Positioning - The FX Super One is positioned to accelerate the Middle East's transition into AI-driven green mobility, with plans for further co-creation initiatives with Iniesta [5] - The company aims to become a key player in the Middle East MPV market, leveraging the FX Super One as a foundational model [5][6]

Core Viewpoint - InnoCare Pharma has initiated a global Phase II clinical trial for its TYK2 inhibitor, Soficitinib, targeting prurigo nodularis in China, marking a significant step in its development pipeline for autoimmune diseases [1][5]. Company Overview - InnoCare Pharma is a biopharmaceutical company focused on developing treatments for cancer and autoimmune diseases, with a commitment to addressing unmet medical needs both in China and globally [6]. Product Development - Soficitinib is a selective TYK2 inhibitor aimed at treating various T-cell related autoimmune disorders, including prurigo nodularis, atopic dermatitis, and vitiligo, among others [2][5]. - The drug works by blocking cytokine signaling pathways associated with itching and inflammation, thereby alleviating symptoms of prurigo nodularis [3]. Market Potential - There are approximately 10 million patients suffering from prurigo nodularis globally, with the market for this condition valued at US$2 billion in 2024 and projected to grow to US$3 billion by 2034 [4].

Core Viewpoint - The announcement highlights Eisai and Biogen's application for lecanemab's subcutaneous formulation in Japan, which, if approved, would be the first at-home injection treatment for Alzheimer's disease in the country [1][2]. Group 1: Product Development and Approval - Eisai has filed a new drug application for lecanemab seeking approval for a subcutaneous autoinjector (SC-AI) in Japan [1]. - The application is based on Phase 3 Clarity AD open-label extension data, confirming that the once-weekly SC-AI 500mg administration is equivalent to the intravenous (IV) administration every two weeks [2]. - If approved, the SC-AI would allow patients to receive treatment at home, reducing the need for hospital visits for IV administration [3]. Group 2: Clinical Efficacy and Safety - Lecanemab targets both protofibrils and amyloid plaques, addressing the underlying neurotoxic processes in Alzheimer's disease [4]. - The safety profile of subcutaneous administration is similar to IV administration, with less than 2% incidence of systemic injection-related reactions [2]. Group 3: Market Presence and Regulatory Status - Lecanemab is currently approved in 51 countries and regions and is under regulatory review in 9 countries [4][9]. - The drug received manufacturing and marketing approval in Japan in September 2023 for treating mild cognitive impairment and mild dementia due to Alzheimer's disease [9]. Group 4: Collaboration and Strategic Alliances - Eisai leads the global development and regulatory submissions for lecanemab, with Biogen co-commercializing and co-promoting the product [5][11]. - The collaboration between Eisai and BioArctic for the development of lecanemab has been ongoing since 2005, with Eisai obtaining global rights for its commercialization [12].

TORONTO, Nov. 27, 2025 (GLOBE NEWSWIRE) -- Optiva Inc. (TSX: OPT) ("Optiva") is pleased to announce that the shareholders of Optiva (the "Shareholders") and the holders (the "Noteholders") of principal amount of 9.75% senior secured payment-in-kind toggle notes ("PIK Notes") have approved the proposed plan of arrangement (the "Arrangement") involving Qvantel Oy (the "Purchaser") at the special meeting of Shareholders (the "Shareholder Meeting") and special meeting of Noteholders (the "Noteholder Meeting" an ...

Core Viewpoint - South Star Battery Metals Corp. has made significant progress in addressing operational issues at its Santa Cruz Graphite Mine, with a successful funding round of US$4.8 million to support plant upgrades and plans to restart production in 2026, indicating a new phase of growth for the company [1][9]. Corporate Highlights During the Quarter - The company appointed Tiago Cunha as Interim CEO, Darren Prins as CFO, and Rogerio Barcellos as General Manager [9]. - A successful private placement raised US$4.8 million, providing sufficient cash to sustain operations through 2026 [9]. - A non-binding term sheet for a US$4 million loan facility with Sprott Streaming was announced, aimed at supporting the strategic plan for the Santa Cruz Graphite Mine [9]. Operations Update - Two critical pieces of equipment for the plant restart have been purchased, with improved delivery timelines; the scrubber's lead time was reduced from 180 days to 90 days at no additional cost [3]. - The company completed additional initiatives under the restructuring plan at no cost, showcasing a cultural transformation and improved productivity [3]. - Installation and commissioning of new equipment are expected to be completed in 2026, allowing for stable production and an anticipated annual output of 5,000 tonnes by mid-2026, with plans to expand capacity to 10,000 tonnes by year-end 2026 [6]. Financial Performance - For the three months ended September 30, 2025, the company reported a loss of $823,278, an improvement from a loss of $1,289,812 in the same period of 2024 [8]. - Loss per share decreased from $0.03 in 2024 to $0.02 in 2025 for the three-month period [8]. - Cash and cash equivalents (excluding the recent raise) stood at $16,010, while total assets increased to $21,128,878 from $20,205,794 in December 2024 [10]. Cost Structure Review - A comprehensive review of the cost structure led to significant savings through contract renegotiations and process optimization, with expected reductions of approximately 60-65% compared to historical costs [4].

Core Viewpoint - Imperial Metals Corporation has successfully completed its 2025 diamond drilling program at the Huckleberry mine, with all nine drillholes intersecting significant mineralization, including copper, molybdenum, silver, and gold [1][3][6]. Group 1: Drilling Program Results - The 2025 drilling program totaled 1,743 meters and successfully intersected mineralization, with drillhole MZ-25-1 showing an elevated gold interval of 22.6 meters at 0.23 g/t gold [1][3]. - Significant intervals from the drilling include various widths and grades of copper, molybdenum, silver, and gold, with notable results from multiple drillholes [5]. - Most mineralization is found in the volcanic rock surrounding the Main Zone stock, with some molybdenum mineralization extending into the stock itself [6]. Group 2: Historical Context and Future Plans - The Huckleberry mine, which operated from 1997 to 2016, is currently inactive but remains an exploration target for the company [2]. - Historical drilling prior to 2020 did not assay for gold or silver, but these metals were present in the copper concentrate produced, and the 2025 drilling results will be integrated into the mine planning [4]. - Additional drilling is being considered for 2026 to further explore the mineralization potential [6]. Group 3: Whiting Creek Prospect - The Whiting Creek prospect, part of the Huckleberry project, is identified as a significant copper-molybdenum exploration target, with three step-out drill holes totaling 1,870 meters completed in 2025 [11]. - Drillholes at Whiting Creek intersected broad zones of low-grade copper and molybdenum mineralization, indicating the potential for further exploration [12][13].

Core Points - Rio2 Limited has participated in a non-brokered private placement of Royal Road Minerals Limited, purchasing 4,166,667 ordinary shares at $0.18 per share, totaling $750,000 [1] - Following this transaction, Rio2 now holds a total of 44,021,667 shares in Royal Road, representing approximately 15% of the issued and outstanding shares on a non-diluted basis [3] - The acquisition of shares is for investment purposes, and Rio2 may acquire additional shares or dispose of its holdings in the future, subject to the Investor Rights Agreement [4] Summary by Sections Investment Details - Rio2 acquired 4,166,667 shares of Royal Road at a price of $0.18 per share, amounting to $750,000 [1] - The purchase allows Rio2 to maintain its pro rata ownership in Royal Road and potentially increase its ownership interest up to 15% [2] Ownership Status - After the private placement, Rio2's total beneficial ownership in Royal Road is 44,021,667 shares, which is approximately 15% of the total shares [3] - Prior to this placement, Rio2 held 39,855,000 shares, also representing around 15% of Royal Road's shares [3] Company Profile - Rio2 is focused on mining operations and development, particularly the Fenix Gold Project in Chile, emphasizing environmental responsibility and sustainable practices [6]

Core Viewpoint - Abcourt Mines Inc. reported significant financial losses in the first quarter of 2025, with a net loss of CAD 7.52 million, primarily due to high costs associated with mining operations and administrative expenses [2][6]. Financial Results Summary - Revenues for the quarter ended September 30, 2025, were CAD 0, while costs of sales amounted to CAD 5,009,786, resulting in a loss from mining operations of CAD 5,009,786 [2]. - Administration expenses increased to CAD 1,416,858 from CAD 775,757 in the previous year, while care and maintenance costs decreased significantly from CAD 887,433 to CAD 29,288 [2]. - Exploration expenses were CAD 250,068, down from CAD 501,160 in the same quarter of 2024, and finance expenses rose to CAD 967,143 from CAD 136,415 [2]. - The net loss per share was CAD 0.01, compared to CAD 0.00 in the prior year [2]. Balance Sheet Overview - As of September 30, 2025, the company had cash reserves of CAD 594,357, a significant decrease from CAD 2,578,587 as of June 30, 2025 [2]. - Total assets increased to CAD 31,811,592 from CAD 21,408,153, while non-current liabilities rose sharply to CAD 28,029,185 from CAD 14,175,891 [2]. - Shareholders' equity showed a negative balance of CAD 5,488,044, worsening from CAD 599,534 [2]. - Working capital, a non-IFRS measure, was CAD 1,288,412, down from CAD 2,952,725 [2][3]. Operational Developments - During the quarter, Abcourt initiated the development of mining operations at the Sleeping Giant site, incurring various expenses related to infrastructure and staffing [6]. - The company began filling the mill's circuit with gold and completed phase 1 of the sleep camp and kitchen, which were commissioned on September 2 [6]. - Civil construction work was also executed at the tailing facility in preparation for winter and future operational lifts planned for Summer 2026 [6]. Market Engagement - Abcourt has engaged Red Cloud Securities Inc. for market-making services, pending approval from the TSX Venture Exchange, to enhance liquidity for its common shares [5][7].

Group 1 - Mustang Energy Corp. has completed the second tranche of milestone payments to Skyharbour Resources Ltd. under the Option Agreement for the 914W Uranium Project, involving a cash payment of $20,000, issuance of 1,098,901 common shares at a deemed price of $0.091 per share, and $100,000 in exploration expenditures [1] - The annual general and special meeting held on November 14, 2025, resulted in the approval of several resolutions, including the election of three directors, the appointment of auditors, and the approval of a plan of arrangement involving Mustang and its subsidiary Allied Strategic Resource Corp. [2] - The British Columbia Supreme Court has rendered a final order approving the Arrangement, with closing subject to customary conditions and approval from the Canadian Securities Exchange for Allied's common shares [3] Group 2 - Mustang Energy is focused on the discovery and development of uranium and critical mineral assets, holding a portfolio of 147,153 hectares in Saskatchewan's Athabasca Basin, a leading uranium district [4]